Adeel A. Butt

Active 1995–2025

152
Papers
18,838
Citations
76
h-index
148
i10-index

Citations

Citations per year for Adeel A. Butt1986: 1 citations1999: 1 citations2001: 1 citations2004: 1 citations2006: 14 citations2007: 16 citations2008: 15 citations2009: 38 citations2010: 34 citations2011: 56 citations2012: 67 citations2013: 103 citations2014: 102 citations2015: 96 citations2016: 95 citations2017: 96 citations2018: 85 citations2019: 399 citations2020: 448 citations2021: 1,187 citations2022: 1,686 citations2023: 716 citations2024: 650 citations2025: 186 citations2026: 6 citations1987–1998: no citations, so these years are not shown2000: no citations, so this year is not shown2002–2003: no citations, so these years are not shown2005: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,010 citing papers, 31.1% of this breakdownUnited Kingdom: 500 citing papers, 7.7% of this breakdownChina: 328 citing papers, 5.1% of this breakdownCanada: 261 citing papers, 4.1% of this breakdownItaly: 235 citing papers, 3.6% of this breakdownGermany: 195 citing papers, 3% of this breakdownQatar: 170 citing papers, 2.6% of this breakdownAustralia: 164 citing papers, 2.5% of this breakdownFrance: 159 citing papers, 2.5% of this breakdownSpain: 143 citing papers, 2.2% of this breakdownSouth Africa: 124 citing papers, 1.9% of this breakdownSwitzerland: 115 citing papers, 1.8% of this breakdown
0%31.1%Other 31.9%

Fields

  • Medicine86.7%
  • Biochemistry, Genetics and Molecular Biology3.8%
  • Immunology and Microbiology2.3%
  • Mathematics1.9%
  • Social Sciences1.7%
  • Health Professions1%
  • Other2.6%

Topics

  • SARS-CoV-2 and COVID-19 Research15%
  • COVID-19 Clinical Research Studies8.1%
  • HIV-related health complications and treatments6.7%
  • Vaccine Coverage and Hesitancy4.3%
  • HIV/AIDS Research and Interventions3.4%
  • COVID-19 epidemiological studies3.1%
  • Other59.4%

Coauthors

All papers

Open in search
  1. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 cited by 576

  2. HIV Infection and the Risk of Acute Myocardial Infarction

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Internal Medicine 2013 cited by 1,349

  3. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 862

  4. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 cited by 454

  5. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

    Authors: , , - New England Journal of Medicine 2021 cited by 1,015

  6. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2021 cited by 468

  7. Microvascular Disease, Peripheral Artery Disease, and Amputation

    Authors: , , , , , , , , , , , , , - Circulation 2019 cited by 191

  8. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2021 cited by 444

  9. Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Cardiology 2017 cited by 309

  10. Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 cited by 140

  11. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 cited by 398

  12. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Infectious Diseases 2023 cited by 113

  13. Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals

    Authors: , , , , , , , , , , , , - JAIDS Journal of Acquired Immune Deficiency Syndromes 2016 cited by 195

  14. Duration of immune protection of SARS-CoV-2 natural infection against reinfection

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Travel Medicine 2022 cited by 106

  15. Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 cited by 83

  16. Weight Change After Antiretroviral Therapy and Mortality

    Authors: , , , , , , , , , , - Clinical Infectious Diseases 2015 cited by 203

  17. Atorvastatin and fluvastatin are associated with dose‐dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES

    Authors: , , , , - Hepatology 2016 cited by 178

  18. Validating Smoking Data From the Veteran's Affairs Health Factors Dataset, an Electronic Data Source

    Authors: , , , , , , , , , , , , , , , , - Nicotine & Tobacco Research 2011 cited by 245

  19. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Scientific Reports 2021 cited by 166

  20. Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - EBioMedicine 2023 cited by 56

  21. Covid-19 Vaccine Protection among Children and Adolescents in Qatar

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 cited by 75

  22. Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Microbe 2022 cited by 74

  23. Protection against Reinfection with the Omicron BA.2.75 Subvariant

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 51

  24. SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting

    Authors: , , , , - Annals of Internal Medicine 2021 cited by 129